Coprologically diagnosing Anoplocephala perfoliata in the presence of A. magna.

A. Bohórquez,A. Meana,N. Pato,M. Luzon

DOI: https://doi.org/10.1016/j.vetpar.2014.04.023

IF: 2.821

2014-08-29

Veterinary Parasitology

Abstract:

What problem does this paper attempt to address?

Mitochondrial DNA abundance in blood is associated with Alzheimer's disease- and dementia-risk

Hannah Stocker,Manuel Gentiluomo,Kira Trares,Léon Beyer,Joshua Stevenson-Hoare,Dan Rujescu,Bernd Holleczek,Konrad Beyreuther,Klaus Gerwert,Ben Schöttker,Daniele Campa,Federico Canzian,Hermann Brenner

DOI: https://doi.org/10.1038/s41380-024-02670-x

2024-07-15

Abstract:The mitochondrial cascade hypothesis of Alzheimer's disease (AD) has been portrayed through molecular, cellular, and animal studies; however large epidemiological studies are lacking. This study aimed to explore the association of mitochondrial DNA copy number (mtDNAcn), a marker representative of mtDNA abundance per cell, with risk of incident all-cause dementia, AD, and vascular dementia diagnosis within 17 years and dementia-related blood biomarkers (P-tau181, GFAP, and NfL). Additionally, sex-stratified analyses were completed. In this German population-based cohort study (ESTHER), 9940 participants aged 50-75 years were enrolled by general practitioners and followed for 17 years. Participants were included in this study if information on dementia status and blood-based mtDNAcn measured via real-time polymerase chain reaction were available. In a nested case-control approach, a subsample of participants additionally had measurements of P-tau181, GFAP, and NfL in blood samples taken at baseline. Of 4913 participants eligible for analyses, 386 were diagnosed with incident all-cause dementia, including 130 AD and 143 vascular dementia cases, while 4527 participants remained without dementia diagnosis within 17 years. Participants with low mtDNAcn (lowest 10%) experienced 45% and 65% percent increased risk of incident all-cause dementia and AD after adjusting for age and sex (all-cause dementia: HRadj, 95%CI:1.45, 1.08-1.94; AD: HRadj, 95%CI: 1.65, 1.01-2.68). MtDNAcn was not associated to vascular dementia diagnosis and was more strongly associated with all-cause dementia among women. In the nested case-control study (n = 790), mtDNAcn was not significantly associated with the dementia-related blood biomarkers (P-tau181, GFAP, and NfL) levels in blood from baseline before dementia diagnosis. This study provides novel epidemiological evidence connecting mtDNA abundance, measured via mtDNAcn, to incident dementia and AD at the population-based level. Reduced mitochondrial abundance may play a role in pathogenesis, especially among women.
Confidence Intervals On Subsets May Be Misleading

J. Shaffer

DOI: https://doi.org/10.22237/JMASM/1099267320

2004-11-01

Abstract:
Blood-Based mtDNA Quantification Indicates Population-Specific Differences Associated with Alzheimer's Disease-Related Risk

Isabelle K. Gorham,Danielle Marie Reid,Jie Sun,Zhengyang Zhou,Robert C. Barber,Nicole R. Phillips

DOI: https://doi.org/10.3233/jad-230880

2024-01-17

Journal of Alzheimer s Disease

Abstract:Background: Age is known to be the biggest risk factor for Alzheimer's disease (AD), and Mexican Americans (MAs), who are one of the fastest-aging populations in the United States, are at a uniquely elevated risk. Mitochondrial stress and dysfunction are key players in the progression of AD and are also known to be impacted by lifestyle and environmental exposures/stressors. Objective: This study aimed to identify population-specific differences in indicators of mitochondrial stress and dysfunction associated with AD risk that are detectable in the blood. Methods: Examining blood from both non-Hispanic white (NHW) and MA participants (N = 527, MA n = 284, NHW n = 243), mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) copy numbers were assessed through quantitative PCR. Data was stratified by population and sample type, and multiple linear regression analyses were performed to identify factors that may influence this phenotype of mitochondrial dysfunction. Results: In the MA cohort, there was a significant relationship between cellular mtDNA:nDNA ratio and body mass index, CDR sum of boxes score, the APOE ɛ2/ɛ3 genotype, and education. Further, there was a significant relationship between cell-free mtDNA copy number and both education and CDR sum score. In the NHW cohort, there was a significant relationship between cellular mtDNA:nDNA ratio and both age and CDR sum score. Age was associated with cell-free mtDNA in the NHW cohort. Conclusions: This evidence supports the existence of population-based differences in the factors that are predictive of this blood-based phenotype of mitochondrial dysfunction, which may be indicative of cognitive decline and AD risk.

neurosciences
Association of Mitochondrial DNA Copy Number With Cardiovascular Disease

Foram N. Ashar,Yiyi Zhang,Ryan J. Longchamps,John Lane,Anna Moes,Megan L. Grove,Josyf C. Mychaleckyj,Kent D. Taylor,Josef Coresh,Jerome I. Rotter,Eric Boerwinkle,Nathan Pankratz,Eliseo Guallar,Dan E. Arking

DOI: https://doi.org/10.1001/jamacardio.2017.3683

2017-11-01

JAMA Cardiology

Abstract:Importance: Mitochondrial dysfunction is a core component of the aging process and may play a key role in atherosclerotic cardiovascular disease. Mitochondrial DNA copy number (mtDNA-CN), which represents the number of mitochondria per cell and number of mitochondrial genomes per mitochondrion, is an indirect biomarker of mitochondrial function.Objective: To determine whether mtDNA-CN, measured in an easily accessible tissue (buffy coat/circulating leukocytes), can improve risk classification for cardiovascular disease (CVD) and help guide initiation of statin therapy for primary prevention of CVD.Design, Setting, and Participants: Prospective, population-based cohort analysis including 21 870 participants (20 163 free from CVD at baseline) from 3 studies: Cardiovascular Health Study (CHS), Atherosclerosis Risk in Communities Study (ARIC), and Multiethnic Study of Atherosclerosis (MESA). The mean follow-up was 13.5 years. The study included 11 153 participants from ARIC, 4830 from CHS, and 5887 from MESA. Analysis of the data was conducted from March 10, 2014, to January 29, 2017.Exposures: Mitochondrial DNA-CN measured from buffy coat/circulating leukocytes.Main Outcomes and Measures: Incident CVD, which combines coronary heart disease, defined as the first incident myocardial infarction or death owing to coronary heart disease, and stroke, defined as the first nonfatal stroke or death owing to stroke.Results: Of the 21 870 participants, the mean age was 62.4 years (ARIC, 57.9 years; MESA, 62.4 years; and CHS, 72.5 years), and 54.7% of participants were women. The hazard ratios for incident coronary heart disease, stroke, and CVD associated with a 1-SD decrease in mtDNA-CN were 1.29 (95% CI, 1.24-1.33), 1.11 (95% CI, 1.06-1.16), and 1.23 (95% CI, 1.19-1.26). The associations persisted after adjustment for traditional CVD risk factors. Addition of mtDNA-CN to the 2013 American College of Cardiology/American Heart Association Pooled Cohorts Equations for estimating 10-year hard atherosclerosis CVD risk was associated with improved risk classification (continuous net reclassification index, 0.194; 95% CI, 0.130-0.258; P < .001). Mitochondrial DNA-CN further improved sensitivity and specificity for the 2013 American College of Cardiology/American Heart Association recommendations on initiating statin therapy for primary prevention of ASCVD (net 221 individuals appropriately downclassified and net 15 individuals appropriately upclassified).Conclusions and Relevance: Mitochondrial DNA-CN was independently associated with incident CVD in 3 large prospective studies and may have potential clinical utility in improving CVD risk classification.

medicine, general & internal
[Carbohydrate, electrolyte and water contents in the cataractous lens of streptozotocin diabetic rats (author's transl)].

H. Ono,S. Hayano

1981-12-10

Abstract:
Epigenome-wide association study of mitochondrial genome copy number

Penglong Wang,Christina A Castellani,Jie Yao,Tianxiao Huan,Lawrence F Bielak,Wei Zhao,Jeffrey Haessler,Roby Joehanes,Xianbang Sun,Xiuqing Guo,Ryan J Longchamps,JoAnn E Manson,Megan L Grove,Jan Bressler,Kent D Taylor,Tuuli Lappalainen,Silva Kasela,David J Van Den Berg,Lifang Hou,Alexander Reiner,Yongmei Liu,Eric Boerwinkle,Jennifer A Smith,Patricia A Peyser,Myriam Fornage,Stephen S Rich,Jerome I Rotter,Charles Kooperberg,Dan E Arking,Daniel Levy,Chunyu Liu,

DOI: https://doi.org/10.1093/hmg/ddab240

IF: 5.1214

2021-08-20

Human Molecular Genetics

Abstract:Abstract We conducted cohort- and race-specific epigenome-wide association analyses of mitochondrial deoxyribonucleic acid (mtDNA) copy number (mtDNA CN) measured in whole blood from participants of African and European origins in five cohorts (n = 6182, mean age = 57–67 years, 65% women). In the meta-analysis of all the participants, we discovered 21 mtDNA CN-associated DNA methylation sites (CpG) (P < 1 × 10−7), with a 0.7–3.0 standard deviation increase (3 CpGs) or decrease (18 CpGs) in mtDNA CN corresponding to a 1% increase in DNA methylation. Several significant CpGs have been reported to be associated with at least two risk factors (e.g. chronological age or smoking) for cardiovascular disease (CVD). Five genes [PR/SET domain 16, nuclear receptor subfamily 1 group H member 3 (NR1H3), DNA repair protein, DNA polymerase kappa and decaprenyl-diphosphate synthase subunit 2], which harbor nine significant CpGs, are known to be involved in mitochondrial biosynthesis and functions. For example, NR1H3 encodes a transcription factor that is differentially expressed during an adipose tissue transition. The methylation level of cg09548275 in NR1H3 was negatively associated with mtDNA CN (effect size = −1.71, P = 4 × 10−8) and was positively associated with the NR1H3 expression level (effect size = 0.43, P = 0.0003), which indicates that the methylation level in NR1H3 may underlie the relationship between mtDNA CN, the NR1H3 transcription factor and energy expenditure. In summary, the study results suggest that mtDNA CN variation in whole blood is associated with DNA methylation levels in genes that are involved in a wide range of mitochondrial activities. These findings will help reveal molecular mechanisms between mtDNA CN and CVD.

genetics & heredity,biochemistry & molecular biology
Genetic Insights into the Association and Causality Between Blood Metabolites and Alzheimer's Disease

Modi Zhai,Yu Zhang,Dongxue Yan,Yuzhen Wang,Wenzhong Li,Jie Sun

DOI: https://doi.org/10.3233/jad-230985

2024-03-13

Journal of Alzheimer s Disease

Abstract:Background: Alzheimer's disease (AD) is an increasing public health concern with the aging of the global population. Understanding the genetic correlation and potential causal relationships between blood metabolites and AD may provide important insights into the metabolic dysregulation underlying this neurodegenerative disorder. Objective: The aim of this study was to investigate the causal relationship between blood metabolites and AD using Mendelian randomization (MR) analysis. Methods: Association data were obtained from three large-scale genome-wide association studies of 486 blood metabolites (N = 7,824), AD (71,880 cases and 383,378 controls), early-onset AD (N = 303,760), and late-onset AD (N = 307,112). Causal associations between blood metabolites and AD were assessed using inverse variance weighting (IVW), MR-Egger, and weighted median methods. Bidirectional two-sample MR analysis was used to identify causal blood metabolites. MR-PRESSO, MR-Egger, and Cochran-Q were used to quantify instrumental variable heterogeneity and horizontal pleiotropy. Results: Using MR and sensitivity analysis, we identified 40 blood metabolites with potential causal associations with AD. After applying false discovery rate (FDR) correction, two metabolites, gamma-glutamylphenylalanine (OR = 1.15, 95% CI: 1.06–1.24, p = 3.88×10–4, q = 0.09) and X-11317 (OR = 1.16, 95% CI: 1.08–1.26, p = 1.14×10–4, q = 0.05), retained significant associations with AD. Reverse MR analysis indicated no significant causal effect of AD on blood metabolites. No significant instrumental variable heterogeneity or horizontal pleiotropy was found. Conclusions: This two-sample MR study provides compelling evidence for a potential causal relationship between blood metabolic dysregulation and susceptibility to AD. Further investigation of the biological relevance of the identified metabolites to AD and additional supporting evidence is warranted.

neurosciences
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain

Hans-Ulrich Klein,Caroline Trumpff,Hyun-Sik Yang,Annie J. Lee,Martin Picard,David A. Bennett,Philip L. De Jager

DOI: https://doi.org/10.1186/s13024-021-00495-8

2021-11-06

Molecular Neurodegeneration

Abstract:Abstract Background Mitochondrial dysfunction is a feature of neurodegenerative diseases, including Alzheimer’s disease (AD). Changes in the mitochondrial DNA copy number (mtDNAcn) and increased mitochondrial DNA mutation burden have both been associated with neurodegenerative diseases and cognitive decline. This study aims to systematically identify which common brain pathologies in the aged human brain are associated with mitochondrial recalibrations and to disentangle the relationship between these pathologies, mtDNAcn, mtDNA heteroplasmy, aging, neuronal loss, and cognitive function. Methods Whole-genome sequencing data from n = 1361 human brain samples from 5 different regions were used to quantify mtDNAcn as well as heteroplasmic mtDNA point mutations and small indels. Brain samples were assessed for 10 common pathologies. Annual cognitive test results were used to assess cognitive function proximal to death. For a subset of samples, neuronal proportions were estimated from RNA-seq profiles, and mass spectrometry was used to quantify the mitochondrial protein content of the tissue. Results mtDNAcn was 7–14% lower in AD relative to control participants. When accounting for all 10 common neuropathologies, only tau was significantly associated with lower mtDNAcn in the dorsolateral prefrontal cortex. In the posterior cingulate cortex, TDP-43 pathology demonstrated a distinct association with mtDNAcn. No changes were observed in the cerebellum, which is affected late by pathologies. Neither age nor gender was associated with mtDNAcn in the studied brain regions when adjusting for pathologies. Mitochondrial content and mtDNAcn independently explained variance in cognitive function unaccounted by pathologies, implicating complex mitochondrial recalibrations in cognitive decline. In contrast, mtDNA heteroplasmy levels increased by 1.5% per year of life in the cortical regions, but displayed no association with any of the pathologies or cognitive function. Conclusions We studied mtDNA quantity and quality in relation to mixed pathologies of aging and showed that tau and not amyloid-β is primarily associated with reduced mtDNAcn. In the posterior cingulate cortex, the association of TDP-43 with low mtDNAcn points to a vulnerability of this region in limbic-predominant age-related TDP-43 encephalopathy. While we found low mtDNAcn in brain regions affected by pathologies, the absence of associations with mtDNA heteroplasmy burden indicates that mtDNA point mutations and small indels are unlikely to be involved in the pathogenesis of late-onset neurodegenerative diseases.

neurosciences
Causal association and mediating effect of blood biochemical metabolic traits and brain image-derived endophenotypes on Alzheimer's disease

Kang-Fu Yin,Xiao-Jing Gu,Wei-Ming Su,Ting Chen,Jiang Long,Li Gong,Zhi-Ye Ying,Meng Dou,Zheng Jiang,Qing-Qing Duan,Bei Cao,Xia Gao,Li-Yi Chi,Yong-Ping Chen

DOI: https://doi.org/10.1016/j.heliyon.2024.e27422

IF: 3.776

2024-03-07

Heliyon

Abstract:Background: Recent genetic evidence supports that circulating biochemical and metabolic traits (BMTs) play a causal role in Alzheimer's disease (AD), which might be mediated by changes in brain structure. Here, we leveraged publicly available genome-wide association study data to investigate the intrinsic causal relationship between blood BMTs, brain image-derived phenotypes (IDPs) and AD. Methods: Utilizing the genetic variants associated with 760 blood BMTs and 172 brain IDPs as the exposure and the latest AD summary statistics as the outcome, we analyzed the causal relationship between blood BMTs and brain IDPs and AD by using a two-sample Mendelian randomization (MR) method. Additionally, we used two-step/mediation MR to study the mediating effect of brain IDPs between blood BMTs and AD. Results: Twenty-five traits for genetic evidence supporting a causal association with AD were identified, including 12 blood BMTs and 13 brain IDPs. For BMTs, glutamine consistently reduced the risk of AD in 3 datasets. For IDPs, specific alterations of cortical thickness (atrophy in frontal pole and insular lobe, and incrassation in superior parietal lobe) and subcortical volume (atrophy in hippocampus and its subgroups, left accumbens and left choroid plexus, and expansion in cerebral white matter) are vulnerable to AD. In the two-step/mediation MR analysis, superior parietal lobe, right hippocampal fissure and left accumbens were identified to play a potential mediating role among three blood BMTs and AD. Conclusions: The results obtained in our study suggest that 12 circulating BMTs and 13 brain IDPs play a causal role in AD. Importantly, a subset of BMTs exhibit shared genetic architecture and potentially causal relationships with brain structure, which may contribute to the alteration of brain IDPs in AD.
Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects

Wei Zhang,Juan I Young,Lissette Gomez,Michael A Schmidt,David Lukacsovich,Achintya Varma,X Steven Chen,Eden R Martin,Lily Wang

DOI: https://doi.org/10.1186/s13195-023-01216-7

2023-04-10

Abstract:Background: Growing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer's disease (AD) and that DNAm differences can be detected in the blood of AD subjects. Most studies have correlated blood DNAm with the clinical diagnosis of AD in living individuals. However, as the pathophysiological process of AD can begin many years before the onset of clinical symptoms, there is often disagreement between neuropathology in the brain and clinical phenotypes. Therefore, blood DNAm associated with AD neuropathology, rather than with clinical data, would provide more relevant information on AD pathogenesis. Methods: We performed a comprehensive analysis to identify blood DNAm associated with cerebrospinal fluid (CSF) pathological biomarkers for AD. Our study included matched samples of whole blood DNA methylation, CSF Aβ42, phosphorylated tau181 (pTau181), and total tau (tTau) biomarkers data, measured on the same subjects and at the same clinical visits from a total of 202 subjects (123 CN or cognitively normal, 79 AD) in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. To validate our findings, we also examined the association between premortem blood DNAm and postmortem brain neuropathology measured on a group of 69 subjects in the London dataset. Results: We identified a number of novel associations between blood DNAm and CSF biomarkers, demonstrating that changes in pathological processes in the CSF are reflected in the blood epigenome. Overall, the CSF biomarker-associated DNAm is relatively distinct in CN and AD subjects, highlighting the importance of analyzing omics data measured on cognitively normal subjects (which includes preclinical AD subjects) to identify diagnostic biomarkers, and considering disease stages in the development and testing of AD treatment strategies. Moreover, our analysis revealed biological processes associated with early brain impairment relevant to AD are marked by DNAm in the blood, and blood DNAm at several CpGs in the DMR on HOXA5 gene are associated with pTau181 in the CSF, as well as tau-pathology and DNAm in the brain, nominating DNAm at this locus as a promising candidate AD biomarker. Conclusions: Our study provides a valuable resource for future mechanistic and biomarker studies of DNAm in AD.
Mitochondrial DNA copy number and incident atrial fibrillation

Di Zhao,Traci M. Bartz,Nona Sotoodehnia,Wendy S. Post,Susan R. Heckbert,Alvaro Alonso,Ryan J. Longchamps,Christina A. Castellani,Yun Soo Hong,Jerome I. Rotter,Henry J. Lin,Brian O’Rourke,Nathan Pankratz,John A. Lane,Stephanie Y. Yang,Eliseo Guallar,Dan E. Arking

DOI: https://doi.org/10.1186/s12916-020-01715-6

IF: 9.3

2020-09-16

BMC Medicine

Abstract:Abstract Background Mechanistic studies suggest that mitochondria DNA (mtDNA) dysfunction may be associated with increased risk of atrial fibrillation (AF). The association between mtDNA copy number (mtDNA-CN) and incident AF in the general population, however, remains unknown. Methods We conducted prospective analyses of 19,709 participants from the Atherosclerosis Risk in Communities Study (ARIC), the Multi-Ethnic Study of Atherosclerosis (MESA), and the Cardiovascular Health Study (CHS). mtDNA-CN from the peripheral blood was calculated from probe intensities on the Affymetrix Genome-Wide Human single nucleotide polymorphisms (SNP) Array 6.0 in ARIC and MESA and from multiplexed real-time quantitative polymerase chain reaction (qPCR) in CHS. Incident AF cases were identified through electrocardiograms, review of hospital discharge codes, Medicare claims, and death certificates. Results The median follow-up time was 21.4 years in ARIC, 12.9 years in MESA, and 11.0 years in CHS, during which 4021 participants developed incident atrial fibrillation (1761 in ARIC, 790 in MESA, and 1470 in CHS). In fully adjusted models, participants with the lowest quintile of mitochondria DNA copy number had an overall 13% increased risk (95% CI 1 to 27%) of incident atrial fibrillation compared to those with the highest quintile. Dose-response spline analysis also showed an inverse association between mitochondria DNA copy number and hazard for atrial fibrillation for all three cohorts. These associations were consistent across subgroups. Conclusions Mitochondria DNA copy number was inversely associated with the risk of AF independent of traditional cardiovascular risk factors. These findings implicate mitochondria DNA copy number as a novel risk factor for atrial fibrillation. Further research is warranted to understand the underlying mechanisms and to evaluate the role of mitochondria DNA copy number in the management of atrial fibrillation risk.

medicine, general & internal
The rate of recovery of intestinal morphology following anthelmintic treatment of parasitised sheep.

K. Angus,R. L. Coop,A. Sykes

DOI: https://doi.org/10.1016/s0034-5288(20)30957-7

IF: 2.554

Research in Veterinary Science

Abstract:
Mitochondrial DNA copy number in autism spectrum disorder and attention deficit hyperactivity disorder: a systematic review and meta-analysis

Ghada Al-Kafaji,Haitham Ali Jahrami,Materah Salem Alwehaidah,Yasmeen Alshammari,Mariwan Husni

DOI: https://doi.org/10.3389/fpsyt.2023.1196035

IF: 4.7

2023-07-06

Frontiers in Psychiatry

Abstract:Background: Several reports suggest that altered mitochondrial DNA copy number (mtDNA-cn), a common biomarker for aberrant mitochondrial function, is implicated in autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD), but the results are still elusive. Methods: A meta-analysis was performed to summarize the current indication and to provide a more precise assessment of the mtDNA-cn in ASD and ADHD. A search in the MEDLINE-PubMed, Scopus, and EMBASE databases was done to identify related studies up to the end of February 2023. The meta-analysis was conducted according to recommendations of the Cochrane Handbook of Systematic Reviews. Results: Fourteen studies involving 666 cases with ASD and ADHD and 585 controls were collected and judged relevant for the systematic review and meta-analysis. The pooled results by a random effects meta-analysis was reported as a geometric mean of the estimated average response ratio and 95% confidence interval. Overall analysis of studies reported differences in mtDNA-cn in blood samples ( k = 10) and non-blood samples (brain tissues and oral samples; k = 4) suggested significantly higher mtDNA-cn in patients compared to controls ( p = 0.0275). Sub-analysis by stratifying studies based on tissue type, showed no significant increase in mtDNA-cn in blood samples among patients and controls ( p = 0.284). Conversely, higher mtDNA-cn was observed in non-blood samples in patients than in controls ( p = 0.0122). Further stratified analysis based on blood-cell compositions as potential confounds showed no significant difference in mtDNA-cn in peripheral blood samples of patients comparted to controls ( p = 0.074). In addition, stratified analysis of aged-matched ASD and ADHD patients and controls revealed no significant difference in mtDNA-cn in blood samples between patients and controls ( p = 0.214), whereas a significant increase in mtDNA-cn was observed in non-blood samples between patients and controls ( p < 0.001). Finally, when the mtDNA-cn was analyzed in blood samples of aged-matched patients with ASD (peripheral blood, leukocytes, and PBMCs) or ADHD (peripheral blood), no significant difference in mtDNA-cn was observed between ASD patients and controls ( p = 0.385), while a significant increase in mtDNA-cn was found between ADHD patients and controls ( p = 0.033). Conclusion: In this first meta-analysis of the evaluation of mtDNA-cn in ASD/ADHD, our results show elevated mtDNA-cn in ASD and ADHD, further emphasizing the implication of mitochondrial dysfunction in neurodevelopmental disorders. However, our results indicate that the mtDNA-cn in blood is not reflected in other tissues in ASD/ADHD, and the true relationship between blood-derived mtDNA-cn and ASD/ADHD remains to be defined in future studies. The importance of blood-cell compositions as confounders of blood-based mtDNA-cn measurement and the advantages of salivary mtDNA-cn should be considered in future studies. Moreover, the potential of mtDNA-cn as a biomarker for mitochondrial malfunction in neurodevelopmental disorders deserves further investigations.

psychiatry
Systems Genetic Identification of Mitochondrion-Associated Alzheimer's Disease Genes and Implications for Disease Risk Prediction

Xuan Xu,Hui Wang,David A. Bennett,Qing-Ye Zhang,Gang Wang,Hong-Yu Zhang

DOI: https://doi.org/10.3390/biomedicines10081782

IF: 4.757

2022-07-25

Biomedicines

Abstract:Cumulative evidence has revealed the association between mitochondrial dysfunction and Alzheimer's disease (AD). Because the number of mitochondrial genes is very limited, the mitochondrial pathogenesis of AD must involve certain nuclear genes. In this study, we employed systems genetic methods to identify mitochondrion-associated nuclear genes that may participate in the pathogenesis of AD. First, we performed a mitochondrial genome-wide association study (MiWAS, n = 809) to identify mitochondrial single-nucleotide polymorphisms (MT-SNPs) associated with AD. Then, epistasis analysis was performed to examine interacting SNPs between the mitochondrial and nuclear genomes. Weighted co-expression network analysis (WGCNA) was applied to transcriptomic data from the same sample (n = 743) to identify AD-related gene modules, which were further enriched by mitochondrion-associated genes. Using hub genes derived from these modules, random forest models were constructed to predict AD risk in four independent datasets (n = 743, n = 542, n = 161, and n = 540). In total, 9 potentially significant MT-SNPs and 14,340 nominally significant MT-nuclear interactive SNPs were identified for AD, which were validated by functional analysis. A total of 6 mitochondrion-related modules involved in AD pathogenesis were found by WGCNA, from which 91 hub genes were screened and used to build AD risk prediction models. For the four independent datasets, these models perform better than those derived from AD genes identified by genome-wide association studies (GWASs) or differential expression analysis (DeLong's test, p < 0.05). Overall, through systems genetics analyses, mitochondrion-associated SNPs/genes with potential roles in AD pathogenesis were identified and preliminarily validated, illustrating the power of mitochondrial genetics in AD pathogenesis elucidation and risk prediction.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
The association of mitochondrial DNA copy number with incident mental disorders in women: A population-based follow-up study

Xiao Wang,Karolina Palmér,Anna Hedelius,Jan Sundquist,Kristina Sundquist,Ashfaque A. Memon

DOI: https://doi.org/10.1016/j.jad.2022.04.064

IF: 6.533

2022-07-01

Journal of Affective Disorders

Abstract:BackgroundAvailable evidence suggests that mitochondrial DNA copy number (mtDNA-CN) may differ among patients with mental disorders compared to the general population. However, whether mtDNA-CN is independently associated with the subsequent incidence of mental disorders remains unclear.Material and methodsWe used droplet digital PCR to measure the absolute mtDNA-CN in DNA samples obtained from a population-based follow-up study, which included a total of 2354 middle-aged women (52–63 years) who were free of mental disorders at baseline. After 17 years (median) of follow-up, 727 participants were diagnosed with mental disorders.ResultsIn the univariate Cox regression, lower baseline mtDNA-CN (mtDNA-CN < 117) was associated with a higher risk of mental disorders (HR = 1.16, p = 0.047). In addition, smoking, marital status and sleeping quality were associated with both mtDNA-CN and mental disorders. After adjusting for these variables, the association between mtDNA-CN and mental disorders decreased and became non-significant (HR = 1.07, p = 0.36). Stratification of data according to the subtype of mental disorders, showed that low mtDNA-CN was associated with a higher risk of alcohol or drug use disorders (HR = 1.82, p = 0.045 after adjusting).ConclusionIn the present study, we could not find any independent association between mtDNA-CN blood and the most common mental disorders in a population-based follow-up study of Swedish women, except for alcohol and drug use disorders. The use of blood mtDNA-CN as a biomarker of mental disorders, in addition to other risk factors, needs to be further examined in future studies.

psychiatry,clinical neurology
Is mitochondrial DNA copy number from human blood associated with iron deposits in the brain?

Qu Tian,David A. Zweibaum,Luke C. Pilling,Francesco Casanova,Yong Qian,Janice L. Atkins,David Melzer,Jun Ding,Luigi Ferrucci

DOI: https://doi.org/10.1089/ars.2023.0529

IF: 7.4675

2024-01-23

Antioxidants & Redox Signaling

Abstract:Iron overload is implicated in mitochondrial dysfunction. Some iron and mitochondria-related measures show sex differences. It is unclear whether mitochondrial DNA copy number (mtDNAcn) from blood associated with iron depositions in the brain or liver and whether the relationship differs by sex. In this population-based study, we find that among community-dwelling adults, lower mtDNAcn assessed in blood is associated with higher brain iron in basal ganglia and hippocampus and more liver fat, and not with brain volumes or liver iron. Interestingly, the association between mtDNAcn and brain iron in basal ganglia is prominent in men. Our observations lead to the hypothesis that mechanisms connecting mitochondrial dysfunction and iron overload may differ between brain and liver and differ by sex.

biochemistry & molecular biology,endocrinology & metabolism
Association between plasma brain-derived neurotrophic factor level and Alzheimer’s disease: a Mendelian randomization study

Jiaxing You,Yinan Wang,Xinyue Chang,Yi Liu,Yu He,Xiya Zhou,Jinyan Zou,Meng Xiao,Mengyao Shi,Daoxia Guo,Ouxi Shen,Zhengbao Zhu

DOI: https://doi.org/10.2174/0115672026281995231227070637

2024-01-25

Current Neurovascular Research

Abstract:Background: High brain-derived neurotrophic factor (BDNF) concentrations have been found to be associated with a decreased risk of Alzheimer’s disease (AD) in observational studies, but the causality for this association remains unclear. Therefore, we aimed to examine the association between genetically determined plasma BDNF levels and AD using a two-sample Mendelian randomization (MR) method. Methods: Twenty single-nucleotide polymorphisms associated with plasma BDNF concentrations were identified as genetic instruments based on a genome-wide association study with 3301 European individuals. Summary-level data on AD were obtained from the International Genomics of Alzheimer’s Project, involving 21,982 AD cases and 41,944 controls of European ancestry. To evaluate the relationship between plasma BDNF concentrations and AD, we employed the inverse-variance weighted method along with a series of sensitivity analyses. Results: The inverse-variance weighted MR analysis showed that genetically determined BDNF concentrations were associated with a decreased risk of AD (odds ratio per SD increase, 0.91; 95% confidence interval, 0.86-0.96; p =0.001). The association between plasma BDNF concentrations and AD was further confirmed through sensitivity analyses using different MR methods, and MR-Egger regression suggested no directional pleiotropy for this association. Conclusion: Genetically determined BDNF levels were associated with a decreased risk of AD, suggesting that BDNF was implicated in the development of AD and might be a promising target for the prevention of AD.

neurosciences,clinical neurology
International blood import/export: recommendations for blood services and software developers

P. Ashford,M. Fearon,R. Bedford

DOI: https://doi.org/10.1111/j.1423-0410.2010.01421.x

2011-04-01

Vox Sanguinis

Abstract:In March 2009, the International Blood Emergency Planning Action Group (IBEPAG) and ICCBBA performed a survey on blood import ⁄ export and labelling [1]. As a follow-up activity, sample blood group labels from fifteen blood services were distributed to ABO ⁄ EBA members to assess the ability of blood services to import blood from other countries, based on label compatibility. Sixteen blood services from fourteen countries participated in this survey. The results show that in some areas compatibility between labels is good, particularly among the Scandinavian blood services who can readily exchange units. However, in spite of the implementation of a ‘universal’ labelling system, there are still significant barriers to reading labels exchanged between countries. There are three main reasons for this: (1) Software limitations imposed by blood establishment computer system (BECS). Many of these systems are configured specifically for local ⁄ national usage and do not permit import of validly labelled ISBT 128 compliant units (see Table 1). (2) Implementation limitations such as the use of national codes, which cannot be interpreted internationally, or non-standard implementation of ISBT 128 (see Table 2). (3) Limitations imposed by regulatory requirements. Similar effect to (1) above but in this case, the software system is capable of processing received units, but configuration parameters set to meet regulatory or accreditation requirements prevent import. An example may be regulatory control over the permitted product codes preventing import of units with valid, but not nationally licensed, products. The goal of ISBT 128 is to enable globally unique identification of donations and to provide standard reference tables, product description terminology and data structures to support the movement of blood components between blood services without the need for relabelling [2]. The system has proven highly effective in facilitating import ⁄ export of blood between blood services within a country [3]. However, this study has shown that a number of barriers to import ⁄ export at an international level remain. In the event of a major emergency severely disrupting national blood supply, import of blood may become an urgent necessity. Ensuring mechanisms exist to safely manage such imports should be a part of blood service emergency plans. This exercise has demonstrated situations where the import of blood was prevented despite labelling being in
Mitochondrial DNA copy number and the risk of autoimmune diseases: A Mendelian randomization study with meta-analysis

Mingzhu Liu,Xiongquan Long,Shuangshuang Fu,Yuyang Zhang,Zihao Liu,Xiaoping Xu,Minghao Wu

DOI: https://doi.org/10.1016/j.jtauto.2024.100251

2024-10-02

Abstract:Background: Mitochondrial DNA plays a crucial role in the pathophysiology of autoimmune diseases (ADs). However, the association between mitochondrial DNA copy number (mtDNA-CN) and ADs risk is controversial. In this study, Mendelian randomization (MR) analysis and meta-analysis were performed using three sets of independent instrumental variables (IVs) to investigate the potential association between mtDNA-CN and 20 types of ADs. Methods: The three sets of IVs were drawn primarily from participants in the UK Biobank and the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium using different methods. Outcome data for ADs were investigated using summary statistics from the FinnGen cohort. The potential causal associations were assessed using inverse-variance weighting (IVW), MR-Egger, and weighted median methods. Sensitivity analysis and the Steiger test were used to verify the robustness of the MR estimates. In addition, a meta-analysis was conducted to pool the results from three IV groups. Results: Overall, genetically predicted mtDNA-CN was not associated with ADs risk (OR = 1.046, 95 % CI: 0.964-1.135, P = 0.283). However, subgroup analyses showed positive causal associations of mtDNA-CN with autoimmune hypothyroidism (OR = 1.133, 95 % CI: 1.016-1.262, P = 0.024) and rheumatoid arthritis (OR = 1.219, 95 % CI: 1.028-1.445, P = 0.023). In contrast, there was no causal association between mtDNA-CN and atopic dermatitis as well as psoriasis, ulcerative colitis, adult-onset Still disease, type1 diabetes, Crohn disease, sarcoidosis, ankylosing spondylitis, multiple sclerosis, autoimmune hyperthyroidism, primary sclerosing cholangitis, systemic lupus erythematosus, systemic sclerosis, alopecia areata, myasthenia gravis, Guillain-Barre syndrome, dermatopolymyositis, and vitiligo. Conclusions: This MR analysis showed mtDNA-CN is causally associated with an increased risk of autoimmune hypothyroidism and rheumatoid arthritis at the genetic level. The findings have important implications for the use of mtDNA-CN as a biomarker for risk assessment of autoimmune hypothyroidism and rheumatoid arthritis in clinical practice.
Investigating Causal Relations Between Circulating Metabolites and Alzheimer’s Diseases: A Mendelian Randomization Study

Shu-Yi Huang,Yu-Xiang Yang,Ya-Ru Zhang,Kevin Kuo,Hong-Qi Li,Xue-Ning Shen,Shi-Dong Chen,Ke-Liang Chen,Qiang Dong,Lan Tan,Jin-Tai Yu

DOI: https://doi.org/10.21203/rs.3.rs-467119/v2

2021-07-19

Abstract:Abstract Background Metabolomics is a promising approach that can be used to understand pathophysiological pathways of Alzheimer disease (AD). However, the relationships between metabolism and AD are poorly understood. The aim of this study is to investigate the causal association between circulating metabolites and risk of AD by combining metabolomics with genomics through two-sample Mendelian randomization (MR) approach. Methods Genetic associations with 123 circulating metabolic traits were utilized as exposures. A large summary statistics data from International Genomics of Alzheimer’s Project was used in primary analysis, including 21,982 AD cases and 41,944 controls. Validation was further performed using family history of AD data from UK Biobank (27,696 cases of maternal AD, 14,338 cases of paternal AD and 272,244 controls). We utilized the inverse-variance weighted method as primary analysis and four additional MR methods (MR-Egger, weighted median, weighted mode, and MR pleiotropy residual sum and outlier) for sensitivity analyses. Results We found one-fold increased risk of developing AD per standard deviation increase in the levels of circulating ApoB (odd ratio (OR)=3.18; 95% confidence interval (CI): 1.52–6.66, P=0.0022) and glycoprotein acetyls (OR=1.21; 95% CI: 1.05–1.39, P=0.0093), serum total cholesterol (OR=2.73; 95% CI: 1.41-5.30, P=0.0030), and low-density lipoprotein (LDL) cholesterol (OR=2.34; 95% CI: 1.53-3.57, P=0.0001). Whereas glutamine (OR=0.81; 95% CI: 0.71-0.92, P=0.0011) were significantly associated with lower risk of AD. We also detected causal effects of several different composition of LDL fractions on increased AD risk, which has been verified in validation. However, we found no association between circulating high-density lipoprotein cholesterol and AD. Conclusions Our findings provided robust evidence supporting causal effects of circulating glycoprotein acetyls, ApoB, LDL cholesterol, and serum total cholesterol on higher risk of AD, whereas glutamine showed the protective effect. Further research is required to decipher the biological pathways underpinning associations.

Coprologically diagnosing Anoplocephala perfoliata in the presence of A. magna.

Mitochondrial DNA abundance in blood is associated with Alzheimer's disease- and dementia-risk

Confidence Intervals On Subsets May Be Misleading

Blood-Based mtDNA Quantification Indicates Population-Specific Differences Associated with Alzheimer's Disease-Related Risk

Association of Mitochondrial DNA Copy Number With Cardiovascular Disease

[Carbohydrate, electrolyte and water contents in the cataractous lens of streptozotocin diabetic rats (author's transl)].

Epigenome-wide association study of mitochondrial genome copy number

Genetic Insights into the Association and Causality Between Blood Metabolites and Alzheimer's Disease

Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain

Causal association and mediating effect of blood biochemical metabolic traits and brain image-derived endophenotypes on Alzheimer's disease

Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects

Mitochondrial DNA copy number and incident atrial fibrillation

The rate of recovery of intestinal morphology following anthelmintic treatment of parasitised sheep.

Mitochondrial DNA copy number in autism spectrum disorder and attention deficit hyperactivity disorder: a systematic review and meta-analysis

Systems Genetic Identification of Mitochondrion-Associated Alzheimer's Disease Genes and Implications for Disease Risk Prediction

The association of mitochondrial DNA copy number with incident mental disorders in women: A population-based follow-up study

Is mitochondrial DNA copy number from human blood associated with iron deposits in the brain?

Association between plasma brain-derived neurotrophic factor level and Alzheimer’s disease: a Mendelian randomization study

International blood import/export: recommendations for blood services and software developers

Mitochondrial DNA copy number and the risk of autoimmune diseases: A Mendelian randomization study with meta-analysis

Investigating Causal Relations Between Circulating Metabolites and Alzheimer’s Diseases: A Mendelian Randomization Study